PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34524919-0	2021	Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir.	Raltegravir Potassium	114-125	FAT atypical cadherin 1	Homo sapiens	6-9	
34524919-1	2021	Integrase inhibitors appear to increase body weight, but paradoxically some data indicate that raltegravir (RAL) may decrease liver fat.	Raltegravir Potassium	95-106	FAT atypical cadherin 1	Homo sapiens	132-135	
32773470-0	2020	Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine.	Raltegravir Potassium	94-105	FAT atypical cadherin 1	Homo sapiens	0-3	
32773470-3	2020	From baseline to 48/96-week, women with ovarian reserve were protected from raltegravir/etravirine-induced weight/fat gain and associated insulin-resistance while peri/postmenopausal women increased weight, fat and insulin-resistance as did men.	Raltegravir Potassium	76-87	FAT atypical cadherin 1	Homo sapiens	114-117